|
Sep 30
|
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
|
|
May 12
|
Ocuphire Pharma First Quarter 2024 Earnings: Misses Expectations
|
|
May 10
|
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
|
|
May 6
|
Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
|
|
May 3
|
Ocuphire Pharma to Present at the Aegis Virtual Conference
|
|
Apr 22
|
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
|
|
Apr 11
|
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
|
|
Apr 1
|
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
|
|
Mar 13
|
Earnings Update: Ocuphire Pharma, Inc. (NASDAQ:OCUP) Just Reported And Analysts Are Trimming Their Forecasts
|
|
Mar 10
|
Ocuphire Pharma Full Year 2023 Earnings: Misses Expectations
|
|
Mar 8
|
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
|
|
Feb 23
|
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
|
|
Jan 4
|
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
|
|
Nov 30
|
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
|
|
Nov 27
|
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Nov 27
|
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
|
|
Jun 27
|
Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association’s Annual Conference
|
|
Jun 21
|
Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference
|
|
Apr 25
|
Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs
|